<DOC>
	<DOCNO>NCT01659008</DOCNO>
	<brief_summary>Treatment Estradiol non-inferior treatment Tranexamic acid reduce amount duration menstrual blood loss woman cyclic heavy menstrual bleeding</brief_summary>
	<brief_title>Estradiol v Lysteda Treatment Heavy Menstrual Bleeding</brief_title>
	<detailed_description>BACKGROUND : The acute onset Heavy Menstrual Bleeding ( HMB ) menses result woman seek care Emergency Department . The current management HMB among resident us combination oral contraceptive oral progestin . The resident Emergency Department often send woman home without therapeutic intervention . There Regulatory Agency approve therapy acute HMB . The etiology HMB well understood . Two potential cause change endometrial prostaglandin increase fibrinolytic activity endometrium . Specific Aim 1 investigate compare effect oral estradiol compare tranexamic acid reduce blood loss duration bleed acute episode HMB . Specific Aim 2 evaluate effect estradiol tranexamic acid possible cause acute HMB measuring prostaglandin Plasminogen activator menstrual effluent end treatment . METHODS : This randomize , double-blind , control , parallel-group , non-inferiority trial , participant age 18 45 year , acute cyclic heavy menstrual bleeding enrol emergency room visit . Participants randomize receive 48 hour ' treatment 1.3 mg oral tranexamic acid 1.0 mg oral estradiol three time day . The primary endpoint reduction amount menstrual effluent . Sample size calculate base detect less 30 ml difference mean menstrual blood loss two treatment group . Amount blood loss quantified alkaline hematin method extraction menstrual pad tampon . Secondary outcome variation hemostatic factor menstrual effluent two treatment group collect menstrual effluent quantitating prostaglandin , Plasminogen activator , Plasminogen activator inhibitor , vascular endothelial growth factor . ANTICIPATED OUTCOMES : The investigator anticipate reduction mean menstrual blood loss treatment group . Compared participant treat estradiol , group treat tranexamic acid statistically significant change reduction menstrual effluent . We also anticipate change different local hemostatic factor menstrual effluent specific treatment arm .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Age : 1845 year old Hemoglobin concentration : le equal 11.5 g/dL , great equal 8.0 g/dL BMI : less equal 35 Menstrual cycle : previous menstrual cycle interval 26 34 day less equal 10 day bleed Contraception : least two month implant removal , six month last depoprovera depoLupron injection , recently ( least 2 month ) discontinue oral , patch intravaginal ring contraceptive On cycle day 13 current menstrual bleeding episode NSAID , aspirin contain medication 48 hour precede current ER visit Estrogen progestin treatment 30 day precede current ER visit Using Paraguard Pregnant lactate History endometrial ablation Women thromboembolic disease , coagulopathy Women history myocardial infarction , cerebrovascular occlusion Uncontrolled high blood pressure ( blood pressure great 150/90 ) Sensitivity estrogen , tranexamic acid</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>acute cyclical heavy menstrual bleeding</keyword>
</DOC>